Cervical Cancer Vaccine Clifton Park NY

The human papillomavirus (HPV) vaccine works for women aged 24 to 45 in Clifton Park who aren't already infected by HPV, the virus that has been linked to cervical cancer and other cervical diseases. That's the finding from Dr. Nubia Munoz, of the National Institute of Cancer in Bogota, Columbia, who noted that women's rising age at first marriage and increasing divorce rates have led to more widespread premarital intercourse and pairing with new sexual partners around middle age.

Local Companies

Robert J Smith
(518) 243-4317
1101 Nott St
Schenectady, NY
MICHAEL KEEFE, MD
(518) 226-6000
3 Care Lane
Saratoga Springs, NY
Timothy Guiney De Eulis, MD
518-445-5015
47 New Scotland Ave
Albany, NY
Muhammad Siddique Tai, MD
518-399-4600
896 Riverview Rd
Rexford, NY
Janet Elaine Gargiulo, MD
518-786-3122
PO Box 610
Latham, NY
Michael E Keefe
(518) 226-6000
3 Care Ln
Saratoga Springs, NY
ELIZABETH VALENTINE, MD
(518) 587-7670
377 Church Street
Saratoga Springs, NY
SYDNEY WELT, MD
(518) 525-6418
317 S Manning Boulevard
Albany, NY
Seah Hooi Lim, MD
47 New Scotland Ave
Albany, NY
Stephen M Hillinger, MD
518-489-0044
317 S Manning Blvd Ste 310
Albany, NY
Data Provided by:
    

Provided By:

TUESDAY, June 2 (HealthDay News) -- The human papillomavirus (HPV) vaccine works for women aged 24 to 45 who aren't already infected by HPV, the virus that has been linked to cervical cancer and other cervical diseases.

That's the finding from Dr. Nubia Munoz, of the National Institute of Cancer in Bogota, Columbia, who noted that women's rising age at first marriage and increasing divorce rates have led to more widespread premarital intercourse and pairing with new sexual partners around middle age.

Their study included more than 3,200 women, aged 24 to 45, with no history of cervical disease or cancer or genital warts caused by HPV types 6, 11, 16 and 18. The women received either the quadrivalent HPV vaccine, which protects against the four HPV types, or a placebo at day one and months two and six of the study.

The women were followed for about 2.2 years and the researchers identified four cases of infection or disease in the vaccinated group, compared to 41 cases in the placebo group. That means the vaccine was 91 percent effective against all four virus strains.

When they looked at only HPV types 16 and 18, the researchers found four cases in the vaccine group and 23 in the placebo group, which means the vaccine was 83 percent effective against those two HPV types.

"Lower effectiveness detected in the mixed population (susceptible women and those who have already acquired HPV infection or HPV-associated disease) suggests that the public health effect of vaccinating women aged 25 to 45 years will be smaller than that recorded after vaccinating susceptible adolescents. This notion will be assessed in future cost-benefit analyses," the study authors wrote.

The findings appear online June 2 and in an upcoming print issue of The Lancet.

More information

The U.S. National Cancer Institute has more about HPV vaccines.

SOURCE: The Lancet, news release, June 1, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com